MarketMoodz
Lilly GLP-1 Growth Accelerates as Novo Braces for 2026 Decline
Eli Lilly guided 2026 sales of $80–$83 billion, signaling about 25% revenue growth and topping consensus. Novo Nordisk, meanwhile, projects a 5%–13% decline in 2026 sales and profits amid U.S. pricing pressures and exclusivity expirations in key markets.
Key Takeaways
- Lilly guides 2026 sales to $80–$83B, about 25% growth and above consensus of roughly $77.6B.
- Novo Nordisk expects 2026 sales and profit to fall 5%–13% due to pricing pressure and expiries in major markets.
- Global GLP-1 pricing headwinds are material, with Lilly forecasting a low- to mid-teens price decline worldwide this year.
- Lilly’s tirzepatide (Zepbound/Mounjaro) is forecast to extend its lead with stronger efficacy and tolerability versus semaglutide.
- Forglipron, Lilly’s obesity pill, is expected to launch in Q2 if approved, and Medicare coverage could lift volumes by adding access for about 40 million beneficiaries.
People Involved
- No specific individuals mentioned
Entities Involved
- Eli Lilly and Company (LLY)Biopharma leading the GLP-1 growth narrative
- Novo Nordisk A/S (NVO)Global GLP-1 competitor facing pricing pressure and exclusivity expirations
- Centers for Medicare & Medicaid Services (CMS)U.S. government agency shaping potential obesity-treatment volumes
MarketMoodz Analysis
For investors, Lilly’s growth trajectory suggests the stock could benefit from a broader re-rating of the GLP-1 space, even as Novo Nordisk faces margin pressure from pricing and exclusivity expirations. The near-term split in growth signals a bifurcated market: faster growth for Lilly on best-in-class injections and direct-to-consumer strategies, versus a more constrained path for Novo in 2026.
Historically, GLP-1s have driven outsized revenue growth as obesity and diabetes care expand, but patent cliffs and payer dynamics are reshaping the trajectory. The shift toward oral pills and expanded Medicare access could alter the competitive balance for years, increasing emphasis on cost of therapy and patient adherence. Watch for FDA decisions on forglipron, payer coverage shifts, and the timing of major patent expirations that could redefine pricing power into the back half of the decade.
Source: Original Article
Get AI-Powered Market Insights
Stay ahead of market-moving events with our real-time analysis and stock ratings.
Start Your Free Trial